Buprenorphine/naloxone: Inhibition of remifentanil analgesia: case report

January 13, 2013

(Source: Reactions) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

A Randomized Trial of Cognitive Behavioral Therapy in Primary Care-based Buprenorphine

December 28, 2012

Abstract: Objective: To determine the impact of cognitive behavioral therapy on outcomes in primary care, office-based buprenorphine/naloxone treatment of opioid dependence. Methods: We conducted a 24-week randomized clinical trial in 141 opioid-dependent patients in a primary care clinic. Patients were randomized to physician management or physician management plus cognitive behavioral therapy. Physician management was brief, […]

Read the full article →

Buprenorphine May Not Be as Safe as You Think: A Pediatric Fatality From Unintentional Exposure

December 19, 2012

We report a fatal exposure to buprenorphine in a small child that occurred after ingestion of a caretaker’s buprenorphine/naloxone. Postmortem toxicology analysis showed free serum concentrations of 52 ng/mL and 39 ng/mL for buprenorphine and norbuprenorphine, respectively. No other drugs were detected. Autopsy did not find signs of injury or trauma. The theoretical safety provided […]

Read the full article →

Feds Ease Access to Suboxone

December 19, 2012

WASHINGTON (MedPage Today) — Patients in U.S. addiction treatment programs will no longer have to wait a year to be eligible for therapy with buprenorphine (Suboxone), according to a new federal rule. (Source: MedPage Today Psychiatry)

Read the full article →

Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers

December 19, 2012

Summary: In rodents, the endogenous opioid system has been implicated in emotion regulation, and in the reduction of fear in particular. In humans, while there is evidence that the opioid antagonist naloxone acutely enhances the acquisition of conditioned fear, there are no corresponding data on the effect of opioid agonists in moderating responses to fear. […]

Read the full article →

Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment

December 19, 2012

Conclusion: Mood and substance use comorbidity is prevalent among patients seeking primary care office-based buprenorphine/naloxone treatment. The findings support the need for clinicians to assess and address these conditions. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction […]

Read the full article →

Buprenorphine May Not Be as Safe as You Think: A Pediatric Fatality From Unintentional Exposure

December 5, 2012

We report a fatal exposure to buprenorphine in a small child that occurred after ingestion of a caretaker’s buprenorphine/naloxone. Postmortem toxicology analysis showed free serum concentrations of 52 ng/mL and 39 ng/mL for buprenorphine and norbuprenorphine, respectively. No other drugs were detected. Autopsy did not find signs of injury or trauma. The theoretical safety provided […]

Read the full article →

Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers

December 5, 2012

Summary: In rodents, the endogenous opioid system has been implicated in emotion regulation, and in the reduction of fear in particular. In humans, while there is evidence that the opioid antagonist naloxone acutely enhances the acquisition of conditioned fear, there are no corresponding data on the effect of opioid agonists in moderating responses to fear. […]

Read the full article →

Suboxone (buprenorphine): one pill can kill

November 16, 2012

3.5 out of 5 stars Buprenorphine May Not Be as Safe as You Think: A Pediatric Fatality From Unintentional Exposure. Kim HK et al. Pediatrics 2012 Nov 5 [Epub ahead of print] Abstract Buprenorphine — a partial agonist at the opioid μ receptors as well as a κ receptor antagonist — is used to treat pain and […]

Read the full article →

Medication Discount Card LLC Adds Suboxone® to its List of Brand…

November 16, 2012

MDC announces the issue of a new Suboxone coupon on its website. A new large-scale study endorses Suboxone as a beneficial treatment for opiate dependence.(PRWeb November 15, 2012)Read the full story at http://www.prweb.com/releases/suboxone/discount/prweb10134506.htm (Source: PRWeb: Medical Pharmaceuticals) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all […]

Read the full article →

← Previous Entries

Next Entries →